Physician profile
Avery D Williamson
NPI 1821548140
$5,134.46
in general payments reported to CMS, 2019-2025
25 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.88 · 2022: $338 · 2023: $1,487 · 2024: $1,310 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,779.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.80 | 2021-2025 | |
| Lilly USA, LLC | $720.74 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $673.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $489.35 | 2022-2025 | |
| Glaxosmithkline, LLC. | $269.20 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $264.24 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $223.09 | 2022-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $197.07 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $194.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $179.84 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $178.09 | 2024-2025 | Voquezna |
| Kyowa Kirin, INC. | $95.67 | 2022-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.89 | 2022-2023 | Stiolto Respimat, Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $61.08 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Indivior INC. | $54.42 | 2024-2025 | Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.13 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $45.89 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $34.03 | 2024 | Nexletol |
| Shield Therapeutics INC | $21.30 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.90 | 2024 | Keveyis |
| Abbott Laboratories | $18.62 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.34 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.44 | 2025 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.